News
Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and
Founded by initial investments from BII (Novo Nordisk Foundation), Vækstfonden (EIFO) and Innovation Fund Denmark,...
Read MoreLophora completes preclinical development of LPH-5 for treatment-resistant depression
Lophora has completed the pre-clinical development of its first-in-class lead candidate LPH-5 for Treatment Resistant...
Read MoreLophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5
Founded by an initial investment of US$1.8M from the BioInnovation Institute (a Novo Nordisk Foundation...
Read MoreLophora Initiates Preclinical Development of LPH-5 for Treatment-Resistant Depression
Lophora has been granted a $1.5M convertible loan by the Novo Nordisk Foundation to advance...
Read More